Clinical trial
Non-randomized Evaluation of the DESolve® Novolimus Eluting Bioresorbable Coronary Scaffold System in de Novo Native Coronary Artery Lesions - DESolve Cx Single-Arm Registry
NCT04034121 is registered in ClinicalTrials.gov with Elixir Medical Corporation as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Non-randomized Evaluation of the DESolve® Novolimus Eluting Bioresorbable Coronary Scaffold System in de Novo Native Coronary Artery Lesions - DESolve Cx Single-Arm Registry
- Lead sponsor
- Elixir Medical Corporation
- Phase
- Not applicable
- Overall status
- Completed
- Start date
- January 20, 2016
- Completion date
- September 30, 2020
- Enrollment
- 50 (actual)
- Sites
- 3
Conditions
As the registry lists them; a condition with its own page is linked.